Cerus Corp
NASDAQ:CERS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cerus Corp
Income from Continuing Operations
Cerus Corp
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cerus Corp
NASDAQ:CERS
|
Income from Continuing Operations
-$15.6m
|
CAGR 3-Years
29%
|
CAGR 5-Years
24%
|
CAGR 10-Years
12%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Income from Continuing Operations
$175.4m
|
CAGR 3-Years
22%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Income from Continuing Operations
$1.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-53%
|
CAGR 10-Years
-27%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Income from Continuing Operations
$410.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
11%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Income from Continuing Operations
$233.6m
|
CAGR 3-Years
103%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Income from Continuing Operations
$128.5m
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
18%
|
|
Cerus Corp
Glance View
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.
See Also
What is Cerus Corp's Income from Continuing Operations?
Income from Continuing Operations
-15.6m
USD
Based on the financial report for Dec 31, 2025, Cerus Corp's Income from Continuing Operations amounts to -15.6m USD.
What is Cerus Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
12%
Over the last year, the Income from Continuing Operations growth was 25%. The average annual Income from Continuing Operations growth rates for Cerus Corp have been 29% over the past three years , 24% over the past five years , and 12% over the past ten years .
